What are the recommended treatment and prophylaxis strategies for respiratory syncytial virus (RSV) infection in infants, including supportive care, aerosolized ribavirin for high‑risk infants, and monoclonal antibodies such as palivizumab and nirsevimab?

Treatment for RSV

Supportive care is the cornerstone of RSV management for most infants and children, with no pharmacologic interventions recommended for routine use, as they show no meaningful impact on morbidity, mortality, or quality of life outcomes. 1

Core Treatment Approach

Supportive Care (Standard Management)

• Oxygen supplementation should be provided if oxygen saturation falls persistently below 90% in previously healthy infants 1
• Hydration support through intravenous or nasogastric fluids is critical for infants unable to maintain adequate oral intake due to respiratory distress 1
• Symptomatic management with acetaminophen or ibuprofen for fever and pain, plus nasal saline irrigation for upper respiratory symptoms 1
• Infants with hemodynamically significant heart or lung disease and premature infants require close monitoring during oxygen weaning 1

What NOT to Use in Routine Cases

• Do not use palivizumab for treatment of established RSV infection—it has no therapeutic benefit and is only for prophylaxis 1
• Do not use bronchodilators routinely, as randomized controlled trials have failed to demonstrate consistent benefit 1
• Do not use corticosteroids routinely in bronchiolitis management 1
• Do not use antibacterial medications unless specific indications of bacterial co-infection exist 1
• Do not use ribavirin routinely in children with bronchiolitis 1

Treatment for High-Risk and Immunocompromised Patients

Aerosolized Ribavirin Indications

• Ribavirin is FDA-approved for hospitalized infants and young children with severe lower respiratory tract infections due to RSV, particularly those with underlying conditions such as prematurity, immunosuppression, or cardiopulmonary disease 2
• Treatment is most effective when instituted within the first 3 days of clinical illness and should be based on documented RSV infection by rapid diagnostic methods 2
• The FDA label specifies that only severe RSV lower respiratory tract infection should be treated with ribavirin, as the vast majority of RSV infections are mild and self-limited 2

Specific High-Risk Populations

• Hematopoietic stem cell transplant (HSCT) recipients with RSV lower respiratory tract infection should receive aerosolized ribavirin as the primary antiviral option 1
• Consider combining ribavirin with immunoglobulin therapy for allogeneic HSCT patients with RSV LRTID or at high risk for progression 1
• Aerosolized ribavirin can be administered as 2 g for 2 hours every 8 hours or as 6 g over 18 hours/day for 7–10 days 3

Intravenous Palivizumab (Off-Label, Limited Use)

• Only very young (age <2 years) allogeneic HSCT patients with LRTID or at high risk for progression might be considered for treatment with intravenous palivizumab at 15 mg/kg body weight 3
• This recommendation is cautious due to lack of robust evidence outside single case reports and very high cost 3

Hospitalization Criteria

• Hypoxemia (SpO2 persistently <90%) is an indication for hospitalization 1
• Signs of severe respiratory distress warrant admission 1
• Inability to maintain adequate oral intake requires hospitalization 1
• Underlying high-risk conditions (immunocompromised status, chronic lung disease, congenital heart disease) are indications for hospitalization 1

Prevention Strategies

Universal Infant Prophylaxis

• Nirsevimab is recommended for all infants aged <8 months who are born during or entering their first RSV season as a single intramuscular injection 1, 4
• Infants and children aged 8–19 months at increased risk for severe RSV disease (chronic lung disease of prematurity, severe immunocompromise, cystic fibrosis with severe lung disease, American Indian/Alaska Native children) should receive nirsevimab entering their second RSV season 4
• Unlike palivizumab, nirsevimab requires only a single dose for the entire RSV season rather than monthly injections 4

Maternal RSV Vaccination Alternative

• Maternal RSV vaccine (RSVpreF/Abrysvo) administered at 32–36 weeks gestation confers passive immunity to the newborn through transplacental antibody transfer 5
• When the mother receives RSV vaccine at least 14 days before delivery, routine nirsevimab administration to the infant is generally not required, except for infants with specific high-risk conditions 5

Legacy Palivizumab Prophylaxis (Now Largely Replaced)

• Palivizumab prophylaxis at 15 mg/kg intramuscularly every 30 days (maximum 5 monthly doses) is recommended for infants born before 29 weeks, 0 days' gestation who are younger than 12 months at the start of RSV season 1
• This has been largely superseded by nirsevimab for most infants 1, 6

Infection Control Measures

• Hand hygiene is the single most important measure to prevent RSV transmission 1
• Use alcohol-based hand rubs before and after direct patient contact if hands are not visibly soiled 1
• Isolation rooms and strict protection measures (gloves, gowning, masks, eye protection) should be applied for HSCT and leukemia patients with respiratory tract infections 3
• Restrict visitors and healthcare workers with respiratory tract infections from access to high-risk patients and wards 3

Universal Prevention Measures for All Infants

• Avoid tobacco smoke exposure completely, as this is a controllable risk factor that increases RSV hospitalization risk 1
• Limit exposure to crowds and group childcare during RSV season (November through March in most U.S. regions) 1
• Keep infants away from sick contacts 1
• Encourage breastfeeding to potentially decrease the risk of lower respiratory tract disease 1
• Ensure influenza vaccination for the infant (starting at 6 months) and all household contacts 1

Common Pitfalls to Avoid

• Do not confuse prophylaxis with treatment: Palivizumab and nirsevimab are preventive agents only and have no role in treating active RSV infection 1
• Do not use ribavirin in mild cases: The FDA label and guidelines emphasize that ribavirin is reserved for severe lower respiratory tract infection in high-risk patients only 2
• Do not continue ribavirin without documented RSV infection: Treatment should not proceed without confirmation by rapid diagnostic methods 2
• Do not administer nirsevimab to infants whose mothers received RSV vaccine ≥14 days before delivery, unless the infant has specific high-risk conditions 5